Glide Pharmaceutical Technologies is a clinical-stage company specializing in solid dose formulations of therapeutics and vaccines. Their focus on developing the SDI, a solid dose injector system, aims to improve patient adherence to long-term self-administered treatments. The organization's pipeline includes solid dose formulations for octreotide, teriparatide, and vaccines for anthrax and influenza. Formerly known as Caretek Medical, Glide Pharmaceutical Technologies continues to innovate in the biotechnology, healthcare, and pharmaceutical industries.
Founded in 2001, the company received a £3.20M Venture Round investment on 01 February 2017. The investors in this round included Invesco, Oxford Technology Management, Oxford Capital, and HYGEA VCT PLC.
